View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 20, 2022

Synaptogenix concludes subject enrolment in Phase IIb Alzheimer’s trial

Topline results from the trial are anticipated during the fourth quarter of this year.

Synaptogenix has concluded subject enrolment in the Phase IIb clinical trial of its lead therapeutic candidate, Bryostatin-1, to treat patients with advanced and moderately severe Alzheimer’s disease (AD). 

A total of 100 subjects were enrolled in the ongoing trial, which is sponsored by the US National Institutes of Health (NIH).

The trial’s independent Data Safety Monitoring Board (DSMB) has confirmed that no drug-associated adverse safety concerns were reported.

Topline results from the trial are anticipated during the fourth quarter of this year.

Patients treated with Bryostatin-1 had substantial cognitive enhancement in the absence of Namenda in two previous consolidated three-month pilot trials while subjects in the placebo arm showed no substantial benefit. 

The present six-month, placebo-controlled trial will have Bryostatin-1 treatment with double the number of doses and randomised enrolment to be controlled for balanced baselines in the treatment and placebo arms. 

As the benefit was priorly seen to last a minimum of 30 days post-dosing, subjects will have been monitored for three months after discontinuing the treatment. 

Synaptogenix president and chief scientific officer Daniel Alkon said: “The absence of any drug-related adverse events, as have been observed with the few other therapeutic strategies reaching limited Food and Drug Administration (FDA) approval for AD, should facilitate our subsequent steps toward clinical utility. 

“Benefits of at least 4.0 SIB scores, above baseline, are likely to be clinically meaningful, and therefore have the potential to treat the underlying disease as well as to provide symptomatic relief.”

Bryostatin-1 showed regenerative mechanisms of action for the rare disease, Fragile X syndrome and other neurodegenerative ailments such as multiple sclerosis, stroke and traumatic brain injury in preclinical studies.

Earlier, it received Orphan Drug Designation from the US FDA to treat Fragile X syndrome.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy